Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, May 6, 2026. Details of the ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

TheFly reported on April 9 that B. Riley Financial increased its price target on NVAX from $16 to $18 while maintaining a Buy ...

Shares of Novavax (NASDAQ: NVAX), a clinical-stage vaccine company focused on developing nanoparticle and recombinant vaccines to treat and prevent a variety of diseases, tanked and fell as much as 11 ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Novavax, Inc. (NASDAQ:NVAX) shares are trading lower Thursday after the company announced it has extended its $225 million convertible notes deal. Additionally, B of A securities downgraded the stock ...

Novavax, Inc. (NASDAQ:NVAX) on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate. Leveraging Novavax’s recombinant, protein-based nanoparticle technology and ...

GAITHERSBURG, Md., Oct. 22, 2025 /PRNewswire/ -- Novavax, Inc. today announced that it has further executed against its planned transformation into a lean, agile operating model by signing definitive ...

GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D). Dr.

The MarketWatch News Department was not involved in the creation of this content. -- Non-exclusive license allows for development by Pfizer to utilize Matrix-M(R) for up to two disease areas with its ...